Swedbank AB Boosts Stake in Jazz Pharmaceuticals PLC $JAZZ

Swedbank AB raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 10.0% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 1,102,143 shares of the specialty pharmaceutical company’s stock after acquiring an additional 100,211 shares during the period. Swedbank AB’s holdings in Jazz Pharmaceuticals were worth $136,831,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in JAZZ. Voya Investment Management LLC increased its position in shares of Jazz Pharmaceuticals by 67.1% during the 1st quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company’s stock valued at $6,996,000 after purchasing an additional 22,628 shares during the last quarter. Inspire Investing LLC bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $689,000. Strs Ohio bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $2,042,000. Acadian Asset Management LLC purchased a new stake in Jazz Pharmaceuticals in the 1st quarter worth approximately $90,000. Finally, Geneos Wealth Management Inc. lifted its holdings in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the sale, the director directly owned 429,973 shares of the company’s stock, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $128.46 on Friday. The stock’s 50-day simple moving average is $118.26 and its 200-day simple moving average is $116.82. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The company has a market capitalization of $7.79 billion, a price-to-earnings ratio of -19.09, a PEG ratio of 7.87 and a beta of 0.24. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same quarter in the previous year, the firm earned $5.30 earnings per share. Jazz Pharmaceuticals’s revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Royal Bank Of Canada increased their price objective on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a report on Thursday, August 28th. Wall Street Zen lowered Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft initiated coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a “buy” rating and a $152.00 price objective for the company. Morgan Stanley lifted their target price on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an “overweight” rating in a report on Thursday, August 28th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $178.67.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.